MedTrace Logo

Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)

NCT00234871 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2008-07-15

No results posted yet for this study

Summary

The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

Conditions

Interventions

DRUG

trandolapril/verapamil

2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD

DRUG

Lotrel (amlodipine/benazepril)

5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD

Sponsors & Collaborators

Principal Investigators

  • Global Medical Information · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234871 on ClinicalTrials.gov